Sentence and cancer type
Showing 41-60 of 75 items.
SentenceCancertype
Transformation of chicken fibroblasts by the v-fms oncogene. None
The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. None
Expression of the c-fms proto-oncogene during human monocytic differentiation. None
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. None
Expression of the c-fms proto-oncogene and of the cytokine, CSF-1, during mouse embryogenesis. None
Nucleotide sequence and structural organization of the human FMS proto-oncogene. None
Transformation of murine fibroblasts by a retrovirus encoding the murine c-fms proto-oncogene. None
Early pre-B-cell transformation induced by the v-fms oncogene in long-term mouse bone marrow cultures. None
The product of the c-fms proto-oncogene: a glycoprotein with associated tyrosine kinase activity. None
Multilineage hematopoietic disorders induced by transplantation of bone marrow cells expressing the v-fms oncogene. None
Transformation by the oncogene v-fms: the effects of castanospermine on transformation-related parameters. None
Modulation of c-fms proto-oncogene expression in human blood monocytes and macrophages. None
Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. None
Genetic mapping of the mouse c-fms proto-oncogene to chromosome 18. None
A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. None
Transformation by the v-fms oncogene product: role of glycosylational processing and cell surface expression. None
The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. None
Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). None
Transformation by the v-fms oncogene product: an analog of the CSF-1 receptor. None
The v-fms oncogene induces factor-independent growth and transformation of the interleukin-3-dependent myeloid cell line FDC-P1. None